The Role of cDNA in Gastric Cancer

[ginfreely]

View attachment 195481

View attachment 195483

 

[ginfreely]

View attachment 195484

 

[ginfreely]

EGFR amplification (15%)

View attachment 195485

 

[ginfreely]

An NGS-based ctDNA analysis revealed genomic alterations, MSI prevalence, and germline BRCA mutations in 85%, 2.5%, and 1.5% of patients, respectively.

MSI only 2.5% of stomach cancer patients. Very rare.